US FDA Staff Says Noven Pharmaceuticals Inc. And Shire Pharmaceuticals ADHD Patch Cannot Be Sold Safely

WASHINGTON, Dec 1 (Reuters) - An experimental skin patch to treat attention deficit hyperactivity disorder in children should not be approved in the United States because it cannot be safely marketed, U.S. regulatory staff said on Thursday.